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An extensive literature demonstrates a relationship between promotional activity towards 
physicians from drug manufacturers and subsequent prescribing of marketed products.  A similar 
association has been demonstrated in a recent study focusing on opioid payments and opioid 
prescribing using multivariate linear regression (Hadland et al.) This article replicates this recent 
study by using updated meal payments and claims data and extends the research by examining 
whether a physician’s specialty, gender, and geographic region of practice help better explain the 
relationship between opioid meal payments and prescribing.  An association was found between 
opioid meal payments and opioid prescribing, which confirms prior study findings.  The analysis 
found that specialty was an important predictor of opioid claims and that pain management 
specialists and physicians in rehabilitation-based specialties are associated with higher opioid 
claims. The analysis did not find evidence to suggest this relationship is different based on 
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The opioid epidemic is undoubtedly one of the most pressing health crises of our time, 
causing an estimated 72,000 deaths in 2017. In recent years, combatting the opioid epidemic with 
urgency has become a focus of the United States public policy. On October 26, 2017, President 
Donald Trump declared the opioid epidemic is a Public Health Emergency under federal law. 
Under this classification, the Secretary of the Department of Health and Human Services (HHS) 
can enact various far-reaching actions to help fight the opioid epidemic, including modifying 
various provisions that could re-allocate funds, personnel, and grants towards this public health 
issue. Even in our divided political environment, the Substance Use-Disorder Prevention that 
Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act was 
passed by the United States Senate on October 3rd, 2018 with an overwhelming majority vote of 
98 to 1. This act includes provisions to address treatment and recovery, prevention, protecting 
communities, and fighting fentanyl. While recent public policy actions by the US make it clear 
that fighting the opioid crisis is one of the nation’s top public health concerns, do these actions 
address the causes of the opioid crisis?    
While there are many factors that contribute to the opioid crisis, one of these factors is 
arguably the influence of the pharmaceutical industry through non-research marketing to 
physicians to influence their prescribing behavior. The link between pharmaceutical marketing 
and physician prescribing in general has been examined in numerous studies, but, there are few 
studies that have focused on opioids specifically. Due to the recent availability of Open Payments 
and Medicare Part D claims data to the general public from the Centers for Medicare and 
Medicaid Services (CMS), there has been an increase in analyses that have examined the 
relationship between pharmaceutical marketing and prescribing activity by joining these 
databases together, which provides a much more complete picture of this relationship available to 
the public than ever before.   
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The purpose of this analysis is to determine whether there is an association between opioid 
meal payments from PSRs to physicians and subsequent physician opioid prescribing. After 
establishing the nature of this relationship, subsequent analyses examined if understanding of this 
association could be enhanced through considering physician demographic characteristics like 
physician gender, state of practice, and specialty.  
The findings of the analysis confirm that there is an association between opioid claims and 
opioid meal payments after controlling for non-meal payments and prior year opioid claims. The 
analysis found that specialty was an important predictor of opioid claims and that pain 
management specialists and physicians in rehabilitation-based specialties are associated with 
higher opioid claims. The analysis did not find much evidence to suggest this relationship is 
different based on the physician gender or region of practice. 
2. Literature Review and Theoretical Framework 
2.1. The Opioid Epidemic 
For more than twenty years, the United States has been in the midst of an opioid epidemic. 
Opioids are a class of narcotics prescribed to patients experiencing acute or chronic pain that can 
either be derived from opium poppy plants or manufactured chemically. According to the World 
Health Organization (WHO), opioids have a high risk of dependence by users and overuse of 
opioids can result in respiratory depression and death. The rates of opioid overdose are increasing 
exponentially over time and this phenomenon is considered an epidemic by organizations like the 
US Food and Drug Administration (FDA) and US Disease Control and Prevention (CDC). This 
crisis imposes an irrefutable medical and economic burden on American citizens.  
According to the CDC, drug overdoses were the leading cause of injury death in the United 
States in 2016. In 2016, there were 63,632 drug overdose fatalities and 42,249 (66.4%) of these 
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deaths directly involved the use of opioids.1 According to the CDC, there has been a 200% 
increase in opioid overdose fatalities between 2000 and 2014.  This rate is accelerating compared 
to a 137% increase in overall drug overdose deaths during the same time period.2  
In addition to costing many American citizens their lives, the opioid epidemic also yields a 
high monetary burden on the American economy. In 2013, Florence et al. estimated the opioid 
epidemic costs $78.5 billion annually based on health care, criminal justice, and loss of 
productivity costs. American taxpayers were estimated to have covered about 25% of these costs 
each year, which include both “direct services through government agencies, but also through tax 
revenue that will be lost from reduced earnings.”3 These monetary costs are likely to increase 
yearly unless there is a decline in opioid deaths, which is unfortunately counter to the current 
trend of increasing annual opioid-related fatalities.  
The origins of the opioid epidemic are multifaceted and complex to derive, but the 
widespread nature of opioid prescribing for medical and non-medical use has been commonly 
traced to an increase of prescribing opioids for pain not related to cancer in the late 1990’s and 
early 2000’s. This change in prescribing behavior is believed to have been caused by patient 
advocacy for the use of opioids for non-cancer chronic pain, the perception that extended-release 
opioids like Purdue Pharma’s OxyContin® were less addictive than prior opioid formulations, an 
easing of legal regulations that would have provided an avenue to prosecute physicians that wrote 
opioid prescriptions in high volumes, and an increase in marketing of opioid products by opioid 
manufacturers.4 
  
                                                          
1. Mattson, Christine L., PhD, Mbabazi Kariisa, PhD, Puja Seth, PhD, Lawrence Scholl, PhD, and Matthew Gladden, PhD. "Morbidity 
and Mortality Weekly Report (MMWR)." Centers for Disease Control and Prevention. August 30, 2018. Accessed October 02, 2018. 
https://www.cdc.gov/mmwr/volumes/67/wr/mm6734a2.htm?s_cid=mm6734a2_w. 
2. Rudd, Rose A., Noah Aleshire, Jon E. Zibbell, and R. Matthew Gladden. "Increases in drug and opioid overdose deaths—United 
States, 2000–2014." American Journal of Transplantation 16, no. 4 (2016): 1323-1327. 
3. Florence, Curtis, Feijun Luo, Likang Xu, and Chao Zhou. "The economic burden of prescription opioid overdose, abuse and 
dependence in the United States, 2013." Medical care 54, no. 10 (2016): 901. 
4. Laxmaiah Manchikanti, M. D., I. I. Standiford Helm, Jeffrey W. Janata MA, Vidyasagar Pampati PhD, Jay S. Grider MSc, and P. 
DO. "Opioid epidemic in the United States." Pain physician 15 (2012): 2150-1149. 
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2.2. Pharmaceutical Payments Towards Physicians 
While many Americans are likely familiar with direct-to-consumer advertising for 
pharmaceutical products on television that emerged in the US in the late 1990’s, many citizens 
may not be aware of the history and continued dominance of pharmaceutical marketing budgets 
on the hiring and deployment of pharmaceutical sales representatives (PSRs) around the country 
dedicated towards the direct selling of their products to physicians through both in-person visits 
and telemarketing.5 Despite the overall positive reception of PSRs by physicians and most 
physicians’ perception that pharmaceutical marketing has no bearing on prescribing decisions, 
countless studies (of methodologies ranging from observational to randomized controlled trials) 
have established an association between physician marketing by PSRs and physician attitudes and 
prescribing behavior.6 
One such study, a randomized controlled trial (RCT) by Grande et al. examined medical 
student attitudes towards pharmaceutical marketing, including level of skepticism, by exposing 
the students to Lipitor marketing promotions. Medical students were unaware the promotion was 
part of the study and students were either part of the University of Pennsylvania School of 
Medicine (UPenn), which restricts pharmaceutical marketing, or the University of Miami School 
of Medicine (Miami), which has less restrictive pharmaceutical marketing policies.  The study 
found that Miami medical students held more favorable views and were less skeptical of 
pharmaceutical marketing than UPenn medical students due to their respective hospital policies 
on PSR drug promotion.7 A more recent continuation of the literature examining the link between 
PSR marketing and physician attitudes was performed by Larkin et al. in 2017, which examined 
prescribing behavior of 2,126 physicians in 19 Academic Medical Centers (AMC) that reduced 
                                                          
5. Mackey, Tim K., Raphael E. Cuomo, and Bryan A. Liang. "The rise of digital direct-to-consumer advertising?: Comparison of 
direct-to-consumer advertising expenditure trends from publicly available data sources and global policy implications." BMC health 
services research 15, no. 1 (2015): 236. 
6. Fickweiler, Freek, Ward Fickweiler, and Ewout Urbach. "Interactions between physicians and the pharmaceutical industry 
generally and sales representatives specifically and their association with physicians’ attitudes and prescribing habits: a systematic 
review." BMJ open 7, no. 9 (2017): e016408. 
7. Grande, David, Dominick L. Frosch, Andrew W. Perkins, and Barbara E. Kahn. "Effect of exposure to small pharmaceutical 
promotional items on treatment preferences." Archives of internal medicine 169, no. 9 (2009): 887-893. 
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access to PSRs between 2006 and 2012. The researchers found that physicians affiliated with 
hospitals with PSR-restrictive policies are associated with a 1.67% decrease in market share for 
products promoted by PSRs.8   
When considering a broad approach to PSR marketing and physician prescribing, 
Fickweiler et al. published a systematic review that explored “interactions between physicians 
and the pharmaceutical industry including sales representatives and their impact on physicians’ 
attitude and prescribing habits.”  Studies published between 1992 and 2016 were included if they 
involved PSRs engaging directly with the doctor and were excluded if they were qualitative, not 
published in an academic journal, and/or if they had a small sample size.  Through the review of 
this literature, researchers found that physicians’ “acceptance of gifts from the company’s PSRs 
have been found to affect physicians’ prescribing behavior and are likely to contribute to 
irrational prescribing of the company’s drug.”6 
2.3. Physician Payments Sunshine Act 
Comparatively lax regulation of PSR marketing payments to physicians, continued scrutiny 
of the relationship between PSR marketing and physician prescribing, and a US political 
environment conducive to passing healthcare reform led to the passage of the Physician Payments 
Sunshine Act (Sunshine Act) by the 111th US Congress as a part of the Patient Protection and 
Affordable Care Act (ACA) of 2010. The Sunshine Act necessitated the reporting of payments, 
transfer of value, or consulting fees (payments) that are greater than 10 US dollars by Group 
Payer Organizations (GPO), Physician-Owned Distributors (POD), and most drug and medical 
device manufacturers. These payments were first reported on March 31st, 2014 by CMS for the 
time period between August 1st, 2013 and December 31st, 2013. Prior to the Sunshine Act, 
organizations like the National Institutes of Health and the FDA required pharmaceutical 
manufacturers to report financial relationships with physicians, but the threshold to report 
                                                          
8. Larkin, Ian, Desmond Ang, Jonathan Steinhart, Matthew Chao, Mark Patterson, Sunita Sah, Tina Wu et al.. "Association between 
academic medical center pharmaceutical detailing policies and physician prescribing." Jama 317, no. 17 (2017): 1785-1795. 
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payments were high for both organizations ($5,000 and $50,000 respectively). 9 One of the 
crucial components of the Sunshine Act for researchers is the requirement to record and publish 
data. To establish transparency on the relationship between pharmaceutical marketing to 
physicians, CMS publishes these payments in the Open Payments database, which is freely 
accessible on the CMS website.10  
Since the Open Payments database was released for public exploration and analysis, there 
have been many recent studies that have examined payment trends from PSRs to physicians by 
linking the Open Payments database to Medicare Part D data. Medicare Part D is the prescription 
drug coverage component of Medicare, which is available to all Medicare beneficiaries and like 
the Open Payments database, this data is available for download on the CMS website.10 
In May 2016, Yeh et al. examined the relationship between PSR marketing and prescribing 
in the context of statin prescribing in Massachusetts. The researchers linked the 2013 Open 
Payments database to Medicare Part D claims data and used linear regression to “analyze the 
association between the intensity of physicians’ industry relationships (as measured by total 
payments) and their prescribing practices, as well as the effects of specific types of payments.”  
The analysis found prescribers that received statin-related payments were more likely to prescribe 
brand-name statins rather than cheaper, non-promoted generic alternatives.11  
In June 2016, Perlis et al. linked 2013 Open Payments data with the Medicare Part D 
Prescriber File, which is a CMS database that contains physician claims, beneficiaries, and other 
data for particular drugs in the scope of Medicare Part-D. The scope of their study was more 
broad and found that among the “12 months of prescribing data from more than 700,000 U.S. 
                                                          
9. Parisi, Thomas J., Isabella M. Ferre, and Harry E. Rubash. "The basics of the sunshine act: how it pertains to the practicing 
orthopedic surgeon." JAAOS-Journal of the American Academy of Orthopedic Surgeons 23, no. 8 (2015): 455-467. 
10. Open Payments. Baltimore, MD: Centers for Medicare & Medicaid Services; 2015. https://openpaymentsdata-origin.cms.gov/ 
11. Yeh, James S., Jessica M. Franklin, Jerry Avorn, Joan Landon, and Aaron S. Kesselheim. "Association of industry payments to 
physicians with the prescribing of brand-name statins in Massachusetts." JAMA internal medicine 176, no. 6 (2016): 763-768. 
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physicians, including analysis of nearly 400,000 individuals within 12 specialties, we find that 
receipt of industry payments is associated with greater prescription cost per beneficiary.” 12 
In August 2016, DeJong et al. performed a cross-sectional analysis of meal payments from 
the 2013 Open Payments database and the 2013 Medicare Part D Prescriber File that focused on 
four target drugs (osuvastatin, nebivolol, olmesartan, and desvenlafaxine). The researchers used a 
“multivariable grouped logistic regression models with binomial physician-level prescribing 
data” that measured the “the association between the number of days that a physician received 
meals related to target drugs and his or her prescribing rate of the promoted drug as a proportion 
of prescriptions in the class.”  As per the other studies, the researchers reported based on their 
analysis that “physicians who received meals related to target drugs had a greater mean 
prescribing volume than those who did not.” 13   
2.4. The Relationship Between Open Payments and Opioid Prescribing 
While existing studies like DeJong et al. have established a relationship between payments 
to physicians in the Open Payments database and physician prescribing, there is little research 
focusing on Open Payments for opioid products and their link to opioid prescribing in the 
Medicare Part D program. 
In 2017, Hadland et al. (2017) integrated and analyzed Open Payments data from 2013-
2015 in an effort to uncover trends among physicians that were marketed opioid products 
specifically. Their analysis used summary statistic techniques like medians, means, and 
interquartile ranges of physician subgroups that received opioid-related payments, such as 
payment types, the US state associated with the physician’s practice, and the physician’s primary 
specialty (primary care, anesthesiology, etc.). Based on their research, 1% of physicians received 
82.5% of total payments in dollars. The highest payments in terms of amount of US dollars were 
                                                          
12. Perlis, Roy H., and Clifford S. Perlis. "Physician payments from industry are associated with greater Medicare Part D prescribing 
costs." PloS one 11, no. 5 (2016): e0155474. 
13. DeJong, Colette, Thomas Aguilar, Chien-Wen Tseng, Grace A. Lin, W. John Boscardin, and R. Adams Dudley. "Pharmaceutical 




for speaking engagements and the highest frequency of payments was for food and beverage 
payments. Most notably, one in eleven US physicians received opioid payments, including one in 
five primary care physicians. Hadland et al. (2017) was one of the earliest studies to specifically 
examine opioid payments to physicians using the Open Payments database.14 
In 2018, Hadland et al. (2018) published a research letter in JAMA Internal Medicine 
entitled “Association of Pharmaceutical Industry Marketing of Opioid Products to Physicians 
with Subsequent Opioid Prescribing,” which extended their prior study from 2017 to examine the 
relationship between opioid payments and opioid prescribing. The researchers found that 
physicians receiving opioid payments were associated with 9.3% greater opioid claims than those 
that did not receive payments for opioids, based on a multiple linear regression model that 
adjusted for 2014 opioid prescription claims and change in total claims between 2015 and 2014. 
The researchers importantly emphasize that this type of observational study cannot establish 
causality. In fact, an alternative explanation could be that prescribers with a greater number of 
claims are targeted specifically by opioid manufacturers to maintain existing prescribing 
behaviors.15  
While existing literature on the relationship between opioid Open Payments and Medicare 
Part D Opioid prescribing examines physician subgroups like payment types, the US state 
associated with the physician’s practice, and the physician’s primary specialty, there is a gap in 
the literature in regard to examining the predictive effect of other physician characteristics that 
may make them more likely to prescribe more opioid products. For example, it could be the case 
that a physician’s gender, geographic area associated with their practice (urban vs. rural), and 
prescribing volume could be statistically significant predictors of opioid prescribing in addition to 
                                                          
14. Hadland, Scott E., Maxwell S. Krieger, and Brandon DL Marshall. "Industry payments to physicians for opioid products, 2013–
2015." American journal of public health 107, no. 9 (2017): 1493-1495. 
15. Hadland, Scott E., Magdalena Cerdá, Yu Li, Maxwell S. Krieger, and Brandon DL Marshall. "Association of pharmaceutical 




receiving opioid Open Payments. Using these physician characteristics to build a profile of 
prescribers could be valuable in understanding predictors of opioid prescribing.   
3. Data and Methods 
3.1. Open Payments 
Open Payments is a comprehensive database maintained and hosted online by CMS 
established by the Sunshine Act that provides transparency between nature of the financial 
relationship between the healthcare industry and physicians. The versions of the database are 
compiled based on the year of the payment transaction. Open Payments was first published in 
2014 for a partial year of 2013 transactions and the latest version of Open Payments is for 
transactions from the year 2017. The focus of this analysis is the relationship between opioid 
prescribing based on prior year opioid claims; due to 2016 opioid claims being the latest year of 
claims data, only 2015 Open Payments were used. According to CMS interactive fact sheet on the 
2015 Open Payments database, over $8.42 billion of payments were exchanged, with $2.7 billion 
of these payments being non-research payments16. 
The database contains fields that pertain to data about the physician or hospital receiving 
the payment, data about the manufacturer or group payer making the payment, and data about the 
payment or payments themselves, including the count and amount of payments, the drugs that 
were marketed during the transaction (between 1-5 drugs listed per database record), and the 
nature of payment. Table 1 examines the frequency of Opioid Payments vs. Total Payments for 
all available natures of payment in the Open Payments data.  The most prevalent form of payment 
for both total payments and only opioid payments is Food and Beverage Payments (meal 
payments). The following example provided by CMS categorizes a typical meal payment: “A 
                                                          
16 "The Facts About Open Payments Data - Open Payments Data - CMS | CMS Open Payments Data." OpenPaymentsData.CMS.gov. 
Accessed December 16, 2018. https://openpaymentsdata.cms.gov/summary. 
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sales person from a drug manufacturer asks a physician if they can talk with them about a new 
drug. They meet over lunch, and the salesperson pays for the meal.” 1718  
Given the prevalence of this type of this type of transfer of funds from PSRs to physicians 
in the context of opioid payments, meal payments are one of the primary variables used in the 
analysis. ‘Non-meal payments’, which are a variable generated based on a compilation of all 
other natures of payment into one categorization, are used in the analysis as a control variable. In 
addition to subsetting the data based on meal and non-meal payments, the data were subset to 
only include opioid payments and meal payments in the United States. Opioid payments were 
identified by using names of brand and generic opioids in CMS’s 2013-2015 Opioid Drug List. A 
database record was included if an opioid product was any of the five possible marketed products 
listed for any one database record. Since Open Payments data are at the transaction-level, the data 
were grouped by physician.  
3.2. Medicare Part D Opioid Claims 
The Medicare Part D Prescriber Summary file is a public CMS database that displays the 
opioid prescribing rates of health care providers that prescribe opioids through the Medicare Part 
D program. The database contains demographic information about health care providers and 
information about claims, including total claims, opioid claims, and extended release opioid 
claims. Medicare Part D is the prescription drug coverage component of Medicare, which 
comprises about 70% of patients covered by Medicare. As mentioned by CMS, this data does not 
include patients that are covered by Medicaid or commercial insurance providers. For privacy 
reasons, data are redacted in situations where there are fewer than 10 opioid claims for any one 
health care provider19.       
                                                          
17 "Natures of Payment." CMS.gov Centers for Medicare & Medicaid Services. September 24, 2014. Accessed December 16, 2018. 
https://www.cms.gov/OpenPayments/About/Natures-of-Payment.html. 
18 "General Payment Data – Detailed Dataset 2015 Reporting Year | CMS Open Payments Data." OpenPaymentsData.CMS.gov. 
Accessed December 16, 2018. https://openpaymentsdata.cms.gov/dataset/General-Payment-Data-Detailed-Dataset-2015-
Reporti/7zxq-8x42. 
19 "General Payment Data – Detailed Dataset 2015 Reporting Year | CMS Open Payments Data." OpenPaymentsData.CMS.gov. 




Table 1 – Open Payment Natures of Payment, Total Payments vs. Opioid Payments 
Nature of Payment Total Payments 
Opioid 
Payments 
Food and Beverage 
10,088,333 199,906 
87.4% 93.2% 






Compensation for services other than consulting, including serving as faculty or as a speaker at a 











Compensation for serving as faculty or as a speaker for a non-accredited and noncertified 
continuing education program 
15,602 6 
0.1% 0.0% 












Current or prospective ownership or investment interest 
4,127 - 
0.0% 0.0% 




Charitable Contribution 1,723 - 
0.0% 0.0% 
 
3.3. Data Aggregation and Analysis Variables 
The Open Payments and Medicare Part D claims databases do not share a primary key or 
other unique identifier. Therefore, to join these two databases together, a combination of 
physician name and zip code were used to match records. The scope of the analysis only included 
physicians that received at least one opioid payment and therefore any unmatched records were 
not included. The data were matched and integrated using R Studio software and the ‘sqldf’ 
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package, which enables the user to run Transact-SQL statement scripts within an R development 
environment. 202122 Table 2 contains a data dictionary of the variables utilized for analysis. 
Table 2 – Analysis Data Dictionary 
Variable Name Variable Type Description 
NPI Primary Key National Provider ID. 
2016 Opioid Claims 
Continuous 
2016 Opioid Claims. Log base 10 transformed 
for analysis. 
2015 Opioid Claims 
Continuous 
2015 Opioid Claims. Log base 10 transformed 
for analysis. 
2015 Meal Payments 
Continuous 
2015 Meal Payments. Log base 10 
transformed for analysis. 
2015 Non-Meal Payments 
Continuous 
2015 Non-Meal Payments. Log base 10 
transformed for analysis. 
Gender Categorical Physician Gender. 
Region Categorical Physician US state region. 
Specialty Group (n=11 variables) Binary 
Dummy variables for each specialty group. 
Variables include Family Practice, Internal 
Medicine, Emergency & Surgery Specialties, 
Pain Specialties, Physical Medicine and 
Rehabilitation, Neurology, Anesthesiology, 
Oncology Specialties, Rheumatology, General 
Practice, Other Specialties (n=58) 
 
3.4. Data Transformation for Analysis 
Before completing any analyses, opioid claims and opioid payments data were 
logarithmically transformed at base 10 (x+1) due to both variables’ right skewed distributions and 
their use in parametric statistical methods, such as ANOVA and multivariate linear regression. 
These transformations were both consistent with the methodology outlined by Hadland et al. and 
yielded residual and quantile-quantile plots that were closest to normal relative to other data 
transformations. Parametric statistical methods were used in favor of non-parametric methods due 
to their robustness and familiarity of interpretability with academics across various disciplines.  
  
                                                          
20 R Core Team (2017). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 
Austria. URL https://www.R-project.org/. 
21 RStudio Team (2015). RStudio: Integrated Development for R. RStudio, Inc., Boston, MA URL http://www.rstudio.com/. 





Table 3 – Multivariate Linear Regression Models Predicting Opioid Claims 
Model Predictors Model 1 Model 2 Model 3 Model 4 
2015 Meal Pay Count 
0.0414*** 0.0350*** 0.0432*** 0.0227*** 
(0.0049) (0.0037) (0.0049) (0.0053) 
2015 Non-Meal Pay Count 
-0.0216* -0.0182* -0.0208* -0.0256** 
(0.0099) (0.0076) (0.0099) (0.0099) 
2015 Opioid Claims 
0.9633*** 0.9682*** 0.9604*** 0.9532*** 
(0.0028) (0.0022) (0.0028) (0.0030) 
Male 
- -0.0024 - - 
  (0.0029)     
Northeast 
- - -0.0136** - 
    (0.0049)   
South 
- - 0.0098* - 
    (0.0041)   
West 
- - -0.0097* - 
    (0.0049)   
Family Practice 
- - - 0.0600*** 
      (0.0078) 
Emergency/Surgery 
- - - 0.0405*** 
      (0.0087) 
Internal Medicine 
- - - 0.0536*** 
      (0.0080) 
Oncology 
- - - 0.0603*** 
      (0.0104) 
Pain 
- - - 0.1093*** 
      (0.0099) 
Rehabilitation 
- - - 0.0935*** 
      (0.0097) 
Neurology 
- - - 0.0334*** 
      (0.0100) 
Anesthesiology 
- - - 0.0838*** 
      (0.0107) 
Rheumatology 
- - - 0.0725*** 
      (0.0118) 
General Practice - - - 0.0382** 
      (0.0147) 
Intercept 
0.0355*** 0.0509*** 0.0418*** 0.0124 
(0.0064) (0.0053) (0.0072) (0.0088) 
Degrees of Freedom 29,517 26,458 29,514 29,507 
Adjusted R2 0.8334 0.9021 0.8336 0.8343 
F-test 49,230 60,930 24,650 11,440 
Significance codes:  0 ‘***’, 0.001 ‘**’, 0.01 ‘*’ 0.05 
  Standard Errors in parentheses 
    
 




4.1. Opioid Payments vs. Opioid Claims 
The purpose of this analysis is to determine whether there is an association between opioid 
meal payments from PSRs to physicians and subsequent physician opioid prescribing. After 
establishing the nature of this relationship, subsequent analyses examine if understanding of this 
association can enhanced through considering physician demographic characteristics like 
physician gender, state of practice, and specialty. Table 3 contains the linear regression 
coefficients, standard error, and significance levels for Models 1, 2, 3, and 4. 
Model 1 is based on a model mentioned by Hadland et al. when examining the relationship 
between opioid prescribing and opioid meal payments. The multivariate linear regression model 
uses 2015 meal payments, 2015 non-meal payments, and 2015 opioid payments as predictors of 
opioid claims. 2015 opioid claims were added as an additional covariate control variable to help 
prevent omitted variable bias for physicians who prescribed many opioids in 2016 due to also 
having prescribed many in opioids 2015 rather than this being explained by meal payments. 2015 
Non-Meal Payments include all other payments to physicians that don’t include meal payments 
(e.g. consulting, lodging) and this variable was included as a control variable to control for any 
other types of payments made to physicians to influence their prescribing behavior. 
This model confirms the findings of Hadland et al. in that opioid meal payments are 
predictive of opioid payments (p < 0.01). More specifically, after the variables are un-
transformed, an increase of 10 opioid meal payments are associated with an increase of 12.5898 
opioid claims after controlling for non-meal payments and prior year opioid prescribing. The 
adjusted R2 of 0.8334 is quite high and indicates the model covariates can jointly explain 83.34% 
of the variance in the outcome of opioid claims. Not only does this result provide confirmatory 
evidence that opioid meal payments are associated with opioid claims, but it also reproduces 
existing research with data from a year after the original study, which provides further evidence 
to support the findings of Hadland et al. 
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4.2. Enhancing understanding of the Opioid Payments vs. Opioid Claims Relationship 
Subsequent analyses introduce physician gender, region of practice, and specialty to help 
further understand the association between opioid payments and claims. Each of the analyses first 
explore the relationship between only the respective subgroups and opioid claims using analysis 
of variance (ANOVA), Tukey Honestly Significant Difference tests (Tukey HSD test), and 
boxplots visualizations. Then, multivariate linear regression models use the subgroups as 
additional covariate predictors to enhance the existing relationship explored in Model 1.  
4.3. Physician Gender & Opioid Payments vs. Opioid Claims 















                                                          
23 H. Wickham. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York, 2009. 
24 Jeffrey B. Arnold (2017). ggthemes: Extra Themes, Scales and Geoms for 'ggplot2'. R package version 3.4.0. https://CRAN.R-
project.org/package=ggthemes 
Table 4 – Physician Summary Statistics, Gender 
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When comparing the difference in means of opioid claims between female physicians and 
male physicians using an ANOVA, there is a statistically significant difference at all conventional 
levels between the group means (p < 0.01). This relationship is also true when comparing male 
and female opioid claims from a quartile perspective. As can be seen visually in Figure 1 and in 
Table 4, it can be observed that male physicians have higher median opioid claims than female 
physicians.  
Model 2 explores whether this difference influences the ability of opioid meal payments to 
predict opioid claims between genders. This model contains the same covariates as Model 1 with 
an additional variable added that identifies whether the physician is male or female. Interestingly, 
the coefficient of the gender variable is not statistically significant at any conventional level (p > 
0.1). This result is a valuable insight, as it shows that there is no significant difference in 
prescribing behavior between male and female physicians and the difference in this relationship 
that can be observed in Figure 1 and Table 4 can actually be attributed to not controlling for non-
meal payments and prior year opioid claims in these simpler models. Practically speaking, this 
result provides evidence to suggest that males are no less susceptible than females when it comes 
to being influenced by pharmaceutical marketing. If gender is viewed in the model as a control 
variable, the addition of this variable makes the model explain 90.21% of the variance in the 
outcome of opioid claims. However, it is important to note that the degrees of freedom are less in 
this model given a number of physicians not having gender disclosed which likely biases this type 




4.4. Physician Region of Practice & Opioid Payments vs. Opioid Claims 

















Table 5 – Physician Summary Statistics, Region 
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To determine whether geographic region is an important factor when considering opioid 
prescribing, the state of a physician’s practice as identified by CMS was classified as Northeast, 
Midwest, South, and West. When comparing the difference in means of opioid claims between 
physicians from Northeast states, Midwest states, South states, and West states using an ANOVA, 
there is a statistically significant difference between the population means (p < 0.01). If this 
relationship is further examined using a Tukey HSD test, there is a statistically significant 
difference between all possible combinations of the group means. This relationship is also true 
when comparing regional opioid claims from a quartile perspective. As can be seen visually in 
Figure 2, it can be observed that physicians from states in the South have the highest median 
opioid claims, while physicians from the Northeast have the lowest median opioid claims and no 
statistical outliers greater than 1.5 standard deviations from the median.    
Model 3 explores whether this difference influences the ability of opioid meal payments to 
predict opioid claims between these regional groups. Model 3 contains the same covariates as 
Model 1 with a categorical variable for each geographic region, except the Midwest region, which 
was excluded by statistical software to avoid the dummy variable trap. The Northeast, South, and 
West coefficients are all statistically significant at the 5% significance level.  However, the effect 
sizes of the regional coefficients are closer to zero, which suggest there is actually not much of a 
meaningful difference between geography and opioid claims. For Northern states, which has the 
largest absolute effect size, going from being a non-Northern state to being a Northern state is 
associated with a -0.0136 decrease in logged opioid claims (about a 1 opioid claim decrease per 
10 opioid meals if untransformed). While this appears to contrast conventional wisdom that 
southern states are associated with higher opioid abuse, this could be confounded by the 
propensity of opioid manufacturers to target specific geographic regions with physician 
marketing versus others, which may differ from geographic regions that have a higher propensity 




4.5. Physician Specialty & Opioid Payments vs. Opioid Claims 














  Table 6 – Physician Summary Statistics, Specialty 
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A physician’s specialty is a crucial factor to consider when analyzing physician prescribing 
activity. The nature of physician prescriptions in terms of type, total quantity, and quantity 
relative to other products are different from a functional perspective for emergency room doctors 
versus dentists versus other types of doctors. When comparing the difference in means and 
quantile distributions, this conventional wisdom is shown to be true. An ANOVA between each 
specialty subgroup shows a statistically significant difference at all conventional levels between 
the group means (p < 0.01). Further, a Tukey HSD test reveals a statistically significant 
difference between all but 6 out of 55 possible combinations of the group means. As can be seen 
visually in Figure 3, pain specialists have the highest median opioid claims only rivaled by 
Anesthesiologists. Perhaps surprisingly, the median opioid claims for Emergency and Surgery 
specialties is one of the lowest; however, there are certainly still many high prescribers that are 
represented as statistical outliers for that particular distribution.    
Model 4 explores whether particular physician specialties influence the ability of opioid 
meal payments to predict opioid claims. This model contains the same covariates as Model 1 with 
dummy variables for each physician specialty group. Unlike the gender and regional models, 
specialty covariates are all significant at all conventional levels (p <0.01). As expected from 
conventional wisdom, pain specialties have the largest model coefficient. In this way, going from 
being a non-pain specialist to a pain specialist is associated with an increase in 1.28 opioid claims 
after controlling for factors like opioid payments, prior year opioid claims, and other top 
physician specialties. This could indicate that pain physicians are more receptive to 
pharmaceutical marketing for opioids than other specialties, which could be a function of their 
medical specialization and the use of opioids as a common treatment for pain.  
5. Conclusion 
The purpose of this analysis is to determine whether there is an association between opioid 
meal payments from PSRs to physicians and subsequent physician opioid prescribing. After 
establishing the nature of this relationship, subsequent analyses examined if understanding of this 
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association could be enhanced through considering physician demographic characteristics like 
physician gender, state of practice, and specialty.  
The findings of the analysis confirm that there is an association between opioid claims and 
opioid meal payments after controlling for non-meal payments and prior year opioid claims. The 
analysis found that specialty was an important predictor of opioid claims and that pain 
management specialists and physicians in rehabilitation-based specialties are associated with 
higher opioid claims. The analysis did not find much evidence to suggest this relationship is 
different based on the physician gender or region of practice. 
5.1. Limitations of Research 
One of the limitations of the research is the CMS Medicare Part D claims data in terms of 
the data’s scope and ability to operationalize its measurement of opioid prescribing. This data 
from a methodological perspective does not provide a complete record of opioid claims due to the 
redaction of data in situations where there are fewer than 10 opioid claims for any one health care 
provider. While this data is the most widely used source of data in prior research examining the 
association between pharmaceutical marketing and physician prescribing in recent years, it is not 
a perfect measure of prescribing. These claims as a measure exclude prescribing that is processed 
through Medicaid and commercial insurance providers. PSR marketing is intended to influence 
all physician prescribing as opposed to only Medicare prescribing and therefore, the data is 
missing part of the analyses’ intended outcome variable due to the lack of availability of this data.  
Another limitation of the research is the error associated with identifying opioid payments 
in the Open Payments data and joining the opioid payments to the opioid claims data. While NDC 
numbers were a field provided by CMS in the Open Payments database, these identifiers were 
often missing and were otherwise in various formats that could not be standardized for systematic 
matching. Therefore, opioid payments were identified by using names of brand and generic 
opioids in CMS’s 2013-2015 Opioid Drug List. Due to this less precise method, a percentage of 
human error is likely introduced. Additionally, the Open Payments and Medicare Part D claims 
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databases do not share a primary key or other unique identifier. Therefore, to join these two 
databases together, a combination of physician name and zip code were used to match records, 
which likely introduces a percentage of human error of both unmatched records and false positive 
matches.  
Finally, it is crucial to emphasize analysis design limitations. Medicare Part D data is 
aggregated by year and therefore, examining Open Payments in year n and comparing to opioid 
claims in year n+1 are the only way to examine opioid payment outcomes. It could the case that 
opioid payments have a much greater effect on physicians a week or month after payment, but the 
effect diminishes after longer time periods. The current scope of the CMS data is not able to 
answer this type of inquiry. Also, any associations described during the course of the analysis do 
not prove causality or directionality. While it was observed that opioid payments are associated 
with opioid claims, this could mean that payments influenced claims or that doctors that prescribe 
opioids were targeted by opioid manufacturers and therefore were more predisposed to these 
claims by design. This research also describes an observational analysis rather than an RCT and 
therefore, there is bias in the model that cannot be controlled. 
5.2. Future Avenues of Research 
Given there are so few analyses that examine the relationship between opioid meal 
payments and opioid claims, there are many avenues of future research. One avenue could be to 
replicate the analysis by replacing the opioid claims data with commercial insurance 
prescriptions. The challenge associated with this type of analysis is that the data are not publically 
available and must be purchased from retail data aggregators like IMS Health or Symphony 
Health. A similar avenue of research could be to replicate the analysis by replacing the opioid 
claims data with opioid fatalities or another variable that identifies opioid abuse to gain an 
understanding of opioid prescriptions that are used as prescribed versus being abused by patients. 
A challenge associated with this analysis may be accounting for opioids not manufactured by 
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pharmaceutical companies that contribute to the opioid epidemic, such as heroin and illicitly 
manufactured synthetic opioids. 
Probably the most impactful future avenue of research would be to design an RCT that can 
reduce as much bias as possible in regard to identifying the effect of pharmaceutical marketing of 
opioids to doctors and those doctors subsequent prescribing of medications. RCTs have been used 
in the context of measuring prescribing behavior in relation to other drugs, but not opioids to the 
author’s knowledge. A design of such a study could be varied, but would require randomization 
of doctors or medical students into a control group and one or more treatment groups. Treatment 
groups could have some kind of restriction of opioid prescribing, have stricter rules against 
pharmaceutical marketing, or be encouraged to prescribe non-opioid anti-inflammatory drugs, 
while the control group may not have such restrictions.  
5.3. Policy Implications 
This analysis provides evidence to suggest that PSR efforts to market to physicians are 
creating the desired effect of increasing opioid prescribing. From a policy perspective, the 
analysis provides policymakers with further evidence to support the Sunshine Act, Physician Data 
Restriction Program, and other programs to make it more difficult for manufacturers to influence 
physicians. This argument is made to varying degrees in numerous other studies that examine 
pharmaceutical marketing, including Hadland et al., who reported “federal and state governments 
should consider legal limits on the number and amount of payments.” A precise solution is 
unclear, but given the opioid epidemic is considered a Public Health Emergency by HHS, this 
research can help justify funding for additional avenues of research through grants. This would be 
a step in the right direction for ultimately furthering the fight against opioid epidemic through 
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